Genetic assay is predictive of prognosis for kidney cancer
the ONA take:
Researchers in Singapore have developed a test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC). ccRCC is the most common type of kidney cancer.
Treatment options include surgery to remove the tumor and tyrosine kinase inhibitor (TKI) therapy. Prognosis for patients, however, is difficult to predict because outcomes vary. This new test identifies genetic markers of different ccRCC subtypes.
In developing this test, the researchers identified eight genes whose expression levels differed between two subtypes of the disease.
Furthermore, the expression profiles of the eight genes proved to reliably predict good or poor prognosis in patients with ccRCC who received TKI therapy as well as underwent surgery.
The researchers report that the assay could be used as a tool to improve surveillance strategies for patients with ccRCC, but clinical trials are needed to determine the assay’s value in relation to various therapies.
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|